{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:51:02Z","timestamp":1792183862271,"version":"4.4.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN-143328"],"award-info":[{"award-number":["FDN-143328"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s40264-024-01434-4","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T18:02:17Z","timestamp":1715191337000},"page":"759-769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dipeptidyl Peptidase-4 Inhibitors and the Risk of Gallbladder and Bile Duct Disease Among Patients with Type 2 Diabetes: A Population-Based Cohort Study"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7957-508X","authenticated-orcid":false,"given":"Samantha B.","family":"Shapiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana H. Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-3556","authenticated-orcid":false,"given":"Laurent","family":"Azoulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"key":"1434_CR1","unstructured":"National Institute for Health and Care Excellence. Guideline: type 2 diabetes in adults: management. London: National Institute for Health And Care Excellence (Nice). Copyright National Institute For Health And Care Excellence; 2015."},{"issue":"Supplement 1","key":"1434_CR2","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.2337\/dc20-S009","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142020. Diabetes Care. 2020;43(Supplement 1):S98\u2013110.","journal-title":"Diabetes Care"},{"key":"1434_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o775","author":"G Moran","year":"2022","unstructured":"Moran G, Bakhai C, Song S, Agwu J. Type 2 diabetes: summary of updated nice guidance. BMJ Br Med J. 2022. https:\/\/doi.org\/10.1136\/bmj.o775.","journal-title":"BMJ Br Med J"},{"key":"1434_CR4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/DMSO.S233538","volume":"13","author":"B Bonora","year":"2020","unstructured":"Bonora B, Avogaro A, Fadini G. Extraglycemic effects of Sglt2 inhibitors: a review of the evidence. Diabet Metab Syndr Obes. 2020;13:161\u201374.","journal-title":"Diabet Metab Syndr Obes"},{"issue":"3\u20134","key":"1434_CR5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","volume":"11","author":"T Filippatos","year":"2014","unstructured":"Filippatos T, Panagiotopoulou T, Elisaf M. Adverse effects of Glp-1 receptor agonists. Rev Diabet Stud. 2014;11(3\u20134):202\u201330.","journal-title":"Rev Diabet Stud"},{"key":"1434_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01793-9","author":"Y Lin","year":"2023","unstructured":"Lin Y, Wang T-H, Tsai M-L, Wu V-C, Tseng C-J, Lin M-S, et al. The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease. Cardiovasc Diabetol. 2023. https:\/\/doi.org\/10.1186\/s12933-023-01793-9.","journal-title":"Cardiovasc Diabetol"},{"key":"1434_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.721135","author":"X Zhao","year":"2021","unstructured":"Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, et al. Glp-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol (Lausanne). 2021. https:\/\/doi.org\/10.3389\/fendo.2021.721135.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"1434_CR8","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamainternmed.2016.1531","volume":"176","author":"J Faillie","year":"2016","unstructured":"Faillie J, Yu O, Yin H, Hillaire-Buys D, Barkun A, Azoulay L. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Intern Med. 2016;176(10):1474\u201381.","journal-title":"JAMA Intern Med"},{"issue":"5","key":"1434_CR9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He L, Wang J, Ping F, Yang N, Huang J, Li Y, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513\u20139.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"1434_CR10","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.2337\/dc19-0415","volume":"42","author":"M Nauck","year":"2019","unstructured":"Nauck M, Muus Ghorbani M, Kreiner E, Saevereid H, Buse J. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the leader randomized trial. Diabetes Care. 2019;42(10):1912\u201320.","journal-title":"Diabetes Care"},{"issue":"1\u20133","key":"1434_CR11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2012.08.005","volume":"179","author":"J Keller","year":"2012","unstructured":"Keller J, Trautmann M, Haber H, Tham L, Hunt T, Mace K, et al. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept. 2012;179(1\u20133):77\u201383.","journal-title":"Regul Pept"},{"issue":"2","key":"1434_CR12","doi-asserted-by":"crossref","first-page":"E72","DOI":"10.2337\/dc22-1095","volume":"46","author":"L He","year":"2022","unstructured":"He L, Wang J, Li Z, Li Y, Zhang H. Dipeptidyl peptidase 4 inhibitors and gallbladder or biliary diseases: data from the U.S. Food and Drug Administration adverse event reporting system. Diabetes Care. 2022;46(2):E72\u20133.","journal-title":"Diabetes Care"},{"issue":"5","key":"1434_CR13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/1753-0407.12351","volume":"8","author":"R Moses","year":"2016","unstructured":"Moses R, Round E, Shentu Y, Golm G, Oneill EA, Gantz I, et al. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. J Diabetes. 2016;8(5):701\u201311.","journal-title":"J Diabetes"},{"issue":"12","key":"1434_CR14","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","volume":"322","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Kahn S, Johansen O, Zinman B, Espeland M, Woerle H, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the Carolina randomized clinical trial. JAMA. 2019;322(12):1155\u201366.","journal-title":"JAMA"},{"issue":"1","key":"1434_CR15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen O, Cooper M, Kahn S, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the Carmelina randomized clinical trial. JAMA. 2019;321(1):69\u201379.","journal-title":"JAMA"},{"issue":"14","key":"1434_CR16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"B Scirica","year":"2013","unstructured":"Scirica B, Bhatt D, Braunwald E, Steg P, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"key":"1434_CR17","doi-asserted-by":"crossref","first-page":"E068882","DOI":"10.1136\/bmj-2021-068882","volume":"377","author":"L He","year":"2022","unstructured":"He L, Wang J, Ping F, Yang N, Huang J, Li W, et al. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials. BMJ. 2022;377:E068882.","journal-title":"BMJ"},{"issue":"3","key":"1434_CR18","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","volume":"44","author":"E Herrett","year":"2015","unstructured":"Herrett E, Gallagher A, Bhaskaran K, Forbes H, Mathur R, Van Staa T, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827\u201336.","journal-title":"Int J Epidemiol"},{"issue":"6","key":"1434_CR19","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/ije\/dyz034","volume":"48","author":"A Wolf","year":"2019","unstructured":"Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, et al. Data resource profile: clinical practice research datalink (CPRD) aurum. Int J Epidemiol. 2019;48(6):1740.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"1434_CR20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2125.2009.03537.x","volume":"69","author":"E Herrett","year":"2010","unstructured":"Herrett E, Thomas S, Schoonen W, Smeeth L, Hall A. Validation and validity of diagnoses in the general practice research database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4\u201314.","journal-title":"Br J Clin Pharmacol"},{"issue":"572","key":"1434_CR21","doi-asserted-by":"crossref","first-page":"E128","DOI":"10.3399\/bjgp10X483562","volume":"60","author":"K Nf","year":"2010","unstructured":"Nf K, Se H, Pw R. Validity of diagnostic coding within the general practice research database: a systematic review. Br J Gen Pract. 2010;60(572):E128\u201336.","journal-title":"Br J Gen Pract"},{"issue":"6779","key":"1434_CR22","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/bmj.302.6779.766","volume":"302","author":"H Jick","year":"1991","unstructured":"Jick H, Jick S, Derby L. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J. 1991;302(6779):766\u20138.","journal-title":"Br Med J"},{"issue":"4","key":"1434_CR23","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/ije\/dyx015","volume":"46","author":"A Herbert","year":"2017","unstructured":"Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P. Data resource profile: hospital episode statistics admitted patient care (HES APC). Int J Epidemiol. 2017;46(4):1093.","journal-title":"Int J Epidemiol"},{"key":"1434_CR24","unstructured":"National Health Service. Hospital episode statistics (HES). Available from https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics."},{"key":"1434_CR25","unstructured":"Office for National Statistics. Deaths. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths."},{"key":"1434_CR26","volume-title":"Up to date","author":"D Wexler","year":"2021","unstructured":"Wexler D. Management of persistent hyperglycemia in type 2 diabetes mellitus. In: Nathan D, Mulder J, editors. Up to date. Waltham, MA: Up to date; 2021."},{"issue":"7","key":"1434_CR27","doi-asserted-by":"crossref","first-page":"E022768","DOI":"10.1136\/bmjopen-2018-022768","volume":"8","author":"S Wilkinson","year":"2018","unstructured":"Wilkinson S, Douglas I, Stirnadel-Farrant H, Fogarty D, Pokrajac A, Smeeth L, et al. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000\u20132017. BMJ Open. 2018;8(7):E022768.","journal-title":"BMJ Open"},{"key":"1434_CR28","doi-asserted-by":"crossref","first-page":"L5657","DOI":"10.1136\/bmj.l5657","volume":"367","author":"RJ Desai","year":"2019","unstructured":"Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367:L5657.","journal-title":"BMJ"},{"issue":"15","key":"1434_CR29","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/sim.3618","volume":"28","author":"I White","year":"2009","unstructured":"White I, Royston P. Imputing missing covariate values for the Cox model. Stat Med. 2009;28(15):1982\u201398.","journal-title":"Stat Med"},{"issue":"2","key":"1434_CR30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/jcpt.12373","volume":"41","author":"V Pizzimenti","year":"2016","unstructured":"Pizzimenti V, Giandalia A, Cucinotta D, Russo G, Smits M, Cutroneo P, et al. Incretin-based therapy and acute cholecystitis: a review of case reports and eudravigilance spontaneous adverse drug reaction reporting database. J Clin Pharm Ther. 2016;41(2):116\u20138.","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"1434_CR31","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamainternmed.2022.3810","volume":"182","author":"D Woronow","year":"2022","unstructured":"Woronow D, Chamberlain C, Niak A, Avigan M, Houstoun M, Kortepeter C. Acute cholecystitis associated with the use of glucagon-like peptide-1 receptor agonists reported to the US Food And Drug Administration. JAMA Intern Med. 2022;182(10):1104\u20136.","journal-title":"JAMA Intern Med"},{"issue":"12","key":"1434_CR32","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/00042737-200012120-00015","volume":"12","author":"S Erlinger","year":"2000","unstructured":"Erlinger S. Gallstones in obesity and weight loss. Eur J Gastroenterol Hepatol. 2000;12(12):1347\u201352.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"1434_CR33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322.","journal-title":"N Engl J Med"},{"key":"1434_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00389","author":"B Gallwitz","year":"2019","unstructured":"Gallwitz B. Clinical use of Dpp-4 inhibitors. Front Endocrinol (Lausanne). 2019. https:\/\/doi.org\/10.3389\/fendo.2019.00389.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1434_CR35","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1053\/j.gastro.2007.04.007","volume":"133","author":"M Marzioni","year":"2007","unstructured":"Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology. 2007;133(1):244\u201355.","journal-title":"Gastroenterology"},{"issue":"7","key":"1434_CR36","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1007\/s11033-014-3302-7","volume":"41","author":"B Chen","year":"2014","unstructured":"Chen B, Zhao W, Dong J, Sima H. Expression of Glp-1r protein and its clinical role in intrahepatic cholangiocarcinoma tissues. Mol Biol Rep. 2014;41(7):4313\u201320.","journal-title":"Mol Biol Rep"},{"issue":"7","key":"1434_CR37","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/gut.2008.150870","volume":"58","author":"M Marzioni","year":"2009","unstructured":"Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, et al. Exendin-4, a glucagon-like peptide 1 receptor agonist protects cholangiocytes from apoptosis. Gut. 2009;58(7):990\u20137.","journal-title":"Gut"},{"issue":"11","key":"1434_CR38","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1111\/dom.13420","volume":"20","author":"C Nex\u00f8e-Larsen","year":"2018","unstructured":"Nex\u00f8e-Larsen C, S\u00f8rensen P, Hausner H, Agersnap M, Baekdal M, Br\u00f8nden A, et al. Effects of liraglutide on gallbladder emptying: a randomized, placebo-controlled trial in adults with overweight or obesity. Diabetes Obes Metab. 2018;20(11):2557\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"1434_CR39","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1210\/jc.2018-01008","volume":"104","author":"I Gether","year":"2019","unstructured":"Gether I, Nex\u00f8e-Larsen C, Knop F. New avenues in the regulation of gallbladder motility-implications for the use of glucagon-like peptide-derived drugs. J Clin Endocrinol Metab. 2019;104(7):2463\u201372.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1434_CR40","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1080\/00365521.2018.1530297","volume":"53","author":"J Rehfeld","year":"2018","unstructured":"Rehfeld J, Knop F, Asmar A, Madsbad S, Holst J, Asmar M. Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of Glp-1-derived drugs. Scand J Gastroenterol. 2018;53(12):1429\u201332.","journal-title":"Scand J Gastroenterol"},{"issue":"10","key":"1434_CR41","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/jcph.940","volume":"57","author":"B Shaddinger","year":"2017","unstructured":"Shaddinger B, Young M, Billiard J, Collins D, Hussaini A, Nino A. Effect of albiglutide on cholecystokinin-induced gallbladder emptying in healthy individuals: a randomized crossover study. J Clin Pharmacol. 2017;57(10):1322\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1434_CR42","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/hep.510240313","volume":"24","author":"R Gebhard","year":"1996","unstructured":"Gebhard R, Prigge W, Ansel H, Schlasner L, Ketover S, Sande D, et al. The role of gallbladder emptying in gallstone formation during diet-induced rapid weight loss. Hepatology. 1996;24(3):544\u20138.","journal-title":"Hepatology"},{"issue":"3","key":"1434_CR43","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/gast.1996.v111.pm8780583","volume":"111","author":"J Pauletzki","year":"1996","unstructured":"Pauletzki J, Althaus R, Holl J, Sackmann M, Paumgartner G. Gallbladder emptying and gallstone formation: a prospective study on gallstone recurrence. Gastroenterology. 1996;111(3):765\u201371.","journal-title":"Gastroenterology"},{"issue":"5","key":"1434_CR44","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/00001574-199309000-00013","volume":"9","author":"WW LaMorte","year":"1993","unstructured":"LaMorte WW. Biliary motility and abnormalities associated with cholesterol cholelithiasis. Curr Opin Gastroenterol. 1993;9(5):810\u20136.","journal-title":"Curr Opin Gastroenterol"},{"issue":"12","key":"1434_CR45","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/dom.12748","volume":"18","author":"M Smits","year":"2016","unstructured":"Smits M, Tonneijck L, Muskiet M, Hoekstra T, Kramer M, Diamant M, et al. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. Diabetes Obes Metab. 2016;18(12):1217\u201325.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1434_CR46","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3748\/wjg.v4.i1.82","volume":"4","author":"T Han","year":"1998","unstructured":"Han T, Zhang S, Tang W, Jiang Z. Bile acids in serum and bile of patients with cholesterol gallstone. World J Gastroenterol. 1998;4(1):82\u20134.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"1434_CR47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"J Lund","year":"2015","unstructured":"Lund J, Richardson D, St\u00fcrmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221\u20138.","journal-title":"Curr Epidemiol Rep"},{"issue":"7","key":"1434_CR48","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","volume":"11","author":"K Yoshida","year":"2015","unstructured":"Yoshida K, Solomon D, Kim S. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015;11(7):437\u201341.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"1434_CR49","doi-asserted-by":"crossref","first-page":"E41562","DOI":"10.1371\/journal.pone.0041562","volume":"7","author":"G Hawthorne","year":"2012","unstructured":"Hawthorne G, Hrisos S, Stamp E, Elovainio M, Francis J, Grimshaw J, et al. Diabetes care provision in UK primary care practices. PLoS ONE. 2012;7(7):E41562.","journal-title":"PLoS ONE"},{"issue":"Suppl 4","key":"1434_CR50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1464-5491.19.s4.5.x","volume":"19","author":"D Williams","year":"2002","unstructured":"Williams D, Baxter H, Airey C, Ali S, Turner B. Diabetes UK funded surveys of the structural provision of primary care diabetes services in the UK. Diabet Med. 2002;19(Suppl 4):21\u20136.","journal-title":"Diabet Med"},{"issue":"1","key":"1434_CR51","doi-asserted-by":"crossref","first-page":"E010210","DOI":"10.1136\/bmjopen-2015-010210","volume":"6","author":"M Sharma","year":"2016","unstructured":"Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open. 2016;6(1):E010210.","journal-title":"BMJ Open"},{"issue":"2","key":"1434_CR52","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jdiacomp.2015.11.012","volume":"30","author":"D Aune","year":"2016","unstructured":"Aune D, Vatten L. Diabetes mellitus and the risk of gallbladder disease: a systematic review and meta-analysis of prospective studies. J Diabetes Complications. 2016;30(2):368\u201373.","journal-title":"J Diabetes Complications"},{"issue":"11","key":"1434_CR53","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1007\/BF02071404","volume":"41","author":"BA Chapman","year":"1996","unstructured":"Chapman BA, Wilson IR, Frampton C, Chisholm R, Stewart N, Eagar G, et al. Prevalence of gallbladder disease in diabetes mellitus. Dig Dis Sci. 1996;41(11):2222\u20138.","journal-title":"Dig Dis Sci"},{"issue":"9","key":"1434_CR54","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.2337\/diacare.16.9.1276","volume":"16","author":"S Haffner","year":"1993","unstructured":"Haffner S, Diehl A, Valdez R, Mitchell B, Hazuda H, Morales P, et al. Clinical gallbladder disease in NIDDM subjects. Relationship to duration of diabetes and severity of glycemia. Diabetes Care. 1993;16(9):1276\u201384.","journal-title":"Diabetes Care"},{"issue":"3","key":"1434_CR55","doi-asserted-by":"crossref","first-page":"E529","DOI":"10.1016\/j.cgh.2020.12.034","volume":"20","author":"S Yuan","year":"2022","unstructured":"Yuan S, Gill D, Giovannucci E, Larsson S. Obesity, type 2 diabetes, lifestyle factors, and risk of gallstone disease: a Mendelian randomization investigation. Clin Gastroenterol Hepatol. 2022;20(3):E529\u201337.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1434_CR56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","volume":"22","author":"C Bailey","year":"2022","unstructured":"Bailey C, Day C, Bellary S. Renal protection with Sglt2 inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep. 2022;22(1):39\u201352.","journal-title":"Curr Diab Rep"},{"issue":"8","key":"1434_CR57","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2174\/1381612826666201103122813","volume":"27","author":"D Karangelis","year":"2021","unstructured":"Karangelis D, Mazer C, Stakos D, Tzifa A, Loggos S, Verma S, et al. Cardio-protective effects of sodium-glucose co-transporter 2 inhibitors: focus on heart failure. Curr Pharm Des. 2021;27(8):1051\u201360.","journal-title":"Curr Pharm Des"},{"issue":"9","key":"1434_CR58","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.3390\/ijms22094416","volume":"22","author":"H Yanai","year":"2021","unstructured":"Yanai H, Hakoshima M, Adachi H, Katsuyama H. Multi-organ protective effects of sodium glucose cotransporter 2 inhibitors. Int J Mol Sci. 2021;22(9):4416.","journal-title":"Int J Mol Sci"},{"key":"1434_CR59","doi-asserted-by":"crossref","first-page":"E071380","DOI":"10.1136\/bmj-2022-071380","volume":"379","author":"R Pradhan","year":"2022","unstructured":"Pradhan R, Lu S, Yin H, Yu OHY, Ernst P, Suissa S, et al. Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. BMJ. 2022;379:E071380.","journal-title":"BMJ"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01434-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01434-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01434-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T08:34:15Z","timestamp":1722242055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01434-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1434"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01434-4","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]},"assertion":[{"value":"15 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was funded by a Foundation Scheme grant from the Canadian Institutes of Health Research (FDN-143328). SBS is the recipient of a doctoral training award from the Canadian Institutes of Health Research. LA is the recipient of a Distinguished Research Scholar Award from the <i>Fonds de recherche du Qu\u00e9bec\u2014Sant\u00e9<\/i> and received a William Dawson Scholar award from McGill University. The study funder was not involved in the design of the study; the collection, analysis, and interpretation of data; and writing the report; and did not impose any restrictions regarding the publication of the report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This study was funded by the Canadian Institutes of Health Research. LA has received speaking and consulting fees from Pfizer and Roche for work unrelated to this project. OY was involved in an advisory board meeting for Novo Nordisk for work unrelated to this study. All other authors declare no conflicts of interest.\u00a0LA\u00a0is an Editorial Board member of <i>Drug Safety<\/i>. LA\u00a0was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"The study protocol was approved by the Research Data Governance of the CPRD (protocol 23_002543) and by the Research Ethics Board of the Jewish General Hospital, Montreal, Canada.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"No data are available. This study is based on data from the CPRD obtained under license from the UK Medicines and Healthcare products Regulatory Agency. The data are provided by patients and collected by the UK National Health Service as part of their care and support. The interpretation and conclusions contained in this study are those of the authors alone. Because electronic health records are classified as \u201csensitive data\u201d by the UK <i>Data Protection Act<\/i>, information governance restrictions (to protect patient confidentiality) prevent data sharing via public deposition. Data are available with approval through the individual constituent entities controlling access to the data. Specifically, the primary care data can be requested via application to the CPRD ().","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Codes may be made privately available upon reasonable request to the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"SBS wrote the manuscript, and all authors edited, critically reviewed, and approved the final version of the manuscript. All authors conceived and designed the study, analyzed and interpreted the data, approved the final version of the manuscript, and are accountable for its accuracy. SBS, HY, and LA performed the statistical analyses. LA acquired the data and supervised the study.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}